PURPOSE: This was an observational, prospective, single-group, multicentre, international study aimed to describe the clinical response, functional impairment, and quality of life (QoL) of patients suffering from major depressive disorder (MDD) and in treatment with Trazodone Once-A-Day (TzOAD) monotherapy, over a 24-week period. PATIENTS AND METHODS: A total of 200 patients with a diagnosis of MDD who had been treated with TzOAD monotherapy were enrolled from 26 sites across 3 European countries (Bulgaria, Czech Republic, and Poland), including psychiatric private practices, and outpatient departments from general and psychiatric hospitals. Study assessments were completed by physicians and patients during routine visits within the normal practice of care. RESULTS: Clinical response was assessed by Clinical Global Impressions - Improvement (CGI-I) responders' percentage at 24 (±4) weeks. The majority of patients (86.5%) reported an improvement on the CGI-I compared to baseline. Results of the study confirm the well-known safety and tolerability of TzOAD, as well as its effectiveness on depressive symptoms, such as improvement in QoL, sleep quality, and overall functioning accompanied by favourable adherence and low drop-out rate. CONCLUSION: To our knowledge, this is the first observational, long-term study in patients suffering from MDD, conducted with TzOAD. The improvement observed in clinical response, overall functioning, depressive symptoms, and QoL along the 24 weeks (+4) maintenance period and the very good retention rate, suggest that TzOAD may represent an effective and well tolerated treatment option for patients suffering from MDD.

3rd Department of Psychiatry and Sleep Disorders Center Institute of Psychiatry and Neurology Warsaw Poland

Department of Psychiatry Medical University of Gdańsk Gdańsk Poland

Diagnostic Consultative Center 14 Hospital VITA Sofia Bulgaria

Global Medical Department Angelini Pharma S p A Rome Italy

Multiprofile Hospital for Active Treatment Medical Clinic Targovishte Bulgaria

Psychiatry and Neurology Brain Soultherapy s r o Kladno Czech Republic

Zobrazit více v PubMed

World Health Organization. Depression; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed April 28, 2023.

Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. CMRO. 2006;22(9):1825–1837. PubMed

Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. doi:10.1176/appi.ajp.163.1.28 PubMed DOI

Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. JCP. 1999;60(4):18118. PubMed

Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. JAD. 2006;91(1):27–32. PubMed

Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and associated factors in patients using newer antidepressant drugs. Gen Hosp Psychiatry. 2015;37(1):46–48. doi:10.1016/j.genhosppsych.2014.10.011 PubMed DOI

Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol. 2002;17(S1):S27–S32. doi:10.1002/hup.386 PubMed DOI

Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(Suppl 16):27–32. PubMed

Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96–106. doi:10.1016/j.curtheres.2005.04.006 PubMed DOI PMC

Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge University Press; 2000.

Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11:875. doi:10.2147/NDT.S73261 PubMed DOI PMC

Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536–546. doi:10.1017/S1092852900024020 PubMed DOI

Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–366. doi:10.4088/JCP.v63n0414 PubMed DOI

Thase ME. Treatment issues related to sleep and depression. J Clin Psychiatry. 2000;61:46–50. PubMed

Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002;22(2):137–147. doi:10.1097/00004714-200204000-00006 PubMed DOI

Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006;60(12):1350–1355. doi:10.1016/j.biopsych.2006.06.015 PubMed DOI

Goldberg H, Finnerty R. A double-blind study of trazodone. Psychopharmacol Bull. 1980;16(3):47–49. PubMed

Patten SB. The comparative efficacy of trazodone and imipramine in the treatment of depression. CMAJ. 1992;146(7):1177. PubMed PMC

Beasley CM, Dornseif BE, Pultz JA, Bosomworth JC, Sayler M. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294–299. PubMed

Falk WE, Rosenbaum JF, Otto MW, Zusky PM, Weilburg JB, Nixon RA. Fluoxetine versus trazodone in depressed geriatric patients. Topics Geriatr. 1989;2(4):208–214. PubMed

Kasper S, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. CMRO. 2005;21(8):1139–1146. PubMed

Namiki M, Eij IM, Minemoto H, et al. A clinical Phase III study of SME3110 (fluvoxamine maleate) in depressed patients at the department of internal medicine. A double-blind, comparative study with trazodone hydrochloride. Clin Ther. 1996;12(4):651–677.

Munizza C, Olivieri L, Loreto GD, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr med res opin. 2006;22(9):1703–1713. doi:10.1185/030079906X121039 PubMed DOI

Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99–106. doi:10.1097/00004714-199404000-00003 PubMed DOI

Fagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-A-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020;35(3):137. doi:10.1097/YIC.0000000000000304 PubMed DOI PMC

Fagiolini A, Comandini A, Dell’Osso MC, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–1049. doi:10.1007/s40263-012-0010-5 PubMed DOI PMC

Hidalgo RB. Trazodone extended release for major depressive disorder. Curr Psychiatr. 2010;9(12):76.

Langlieb AM, Guico-Pabia CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion CNS Disord. 2010;12(2):26705. PubMed PMC

Solomon DA, Leon AC, Endicott J, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45(6):423–430. doi:10.1016/j.comppsych.2004.07.002 PubMed DOI

Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Focus. 2006;148(2):997. PubMed

Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.

Feng YS, Kohlman T, Janssen MF, Bucholz I. Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2021;30:647–673. doi:10.1007/s11136-020-02688-y PubMed DOI PMC

Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727. doi:10.1007/s11136-012-0322-4 PubMed DOI PMC

Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)0. Qual Life Res. 2011;20(10):1727–1736. doi:10.1007/s11136-011-9903-x PubMed DOI PMC